Session information

Symposium

[S54] What is required to advance the seeds of DDS technology at the basic research to the development stage

Sun. Mar 31, 2024 9:45 AM - 11:45 AM [Room 301] Conference Center 301 (3F)

Organizer: Hiromu Kondo (Sch. Pharm. Sci., Univ. of Shizuoka), Ryo Suzuki (Fac. Pharma-Sci., Teikyo Univ.)

Lipid nanoparticles (LNPs) loaded with mRNA have been used in worldwide as a vaccine against novel coronavirus infection. The LNPs were produced by the accumulation of basic data in academia and venture companies from research conducted before the COVID-19 pandemic, the cultivation of DDS seeds, continued improvements, and collaboration toward their practical application.
This development process is thought to have involved a variety of trial and error, technological refinement, and a search for collaboration. This led to its practical application as a vaccine against COVID-19. On the other hand, not all DDS technologies have led to practical application, even though similar actions have been taken. Why is this? In this symposium, we would like to consider this question. Particularly, we will discuss the points that are necessary for the seeds of DDS technology to take steps toward practical application. And we would like to hear from venture companies that are developing basic-level DDS seeds for commercialization and from speakers who are involved in R&D funding, to hear their real voices in drug discovery venture startups, and to organize what is required to advance basic research to the development stage. We would also like to discuss future actions and prospects. We hope that this symposium will contribute to the fruition of excellent DDS formulation research originating in Japan into clinical application.